Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma
Status:
Terminated
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
A randomized controlled study is conducted on unresectable advanced gastric carcinoma and
recurrent gastric carcinoma to compare TS-1 therapy with TS-1 + PSK therapy. The primary
endpoint of this study is progression-free survival (PFS), with secondary endpoints of
anticancer effect, time to treatment failure (TTF), QOL (FACT-BRM), compliance, adverse drug
reactions and immunological factors.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Eastern Network of Cancer Immunological Therapy, Japan